Recombinant E. coli Chlorogenic Acid Biosynthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing chlorogenic acid, such as plant extraction and traditional chemical synthesis, face inefficiencies due to seasonal availability and low yields, and biosynthesis methods struggle with flux imbalances and cofactor consumption in E. coli and Saccharomyces cerevisiae systems.
Innovation Solution
A recombinant E. coli strain is engineered to express hydroxycinnamoyl CoA:quinic acid transferase and 4-coumarate:CoA ligase, with modifications including knockout of thioesterase and overexpression of specific enzymes to balance pathways and increase cofactor availability, allowing for efficient biosynthesis of chlorogenic acid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plant extraction methods are used to produce chlorogenic acid, then the product can be obtained from natural sources, but the production efficiency is low due to seasonal availability and low plant tissue content
Solution Approach 1:
The patent replaces mechanical plant extraction methods with a biological synthesis system using engineered E. coli. The mechanical/biological extraction process from plants is substituted by a controlled microbial fermentation system that produces chlorogenic acid through engineered metabolic pathways, eliminating seasonal dependencies and low tissue content limitations.
Solution Approach 2:
The engineered E. coli strain synthesizes chlorogenic acid using its own metabolic pathways and endogenous precursors. The bacterium utilizes its native shikimate pathway intermediates and engineered enzymatic routes to self-produce the target compound, eliminating the need for external plant material and achieving continuous production independent of seasonal variations.
2Ease of manufacture
If traditional chemical synthesis methods are used, then chlorogenic acid can be produced through multi-step reactions, but the yields are low and the process is not suitable for large-scale production
Solution Approach 1:
The patent replaces traditional chemical synthesis methods with a biological catalysis system. Complex multi-step chemical reactions are substituted by enzymatic catalysis within engineered E. coli, where biological catalysts (enzymes) facilitate the formation of chlorogenic acid through controlled metabolic pathways, improving both feasibility and scalability.
Solution Approach 2:
The patent optimizes multiple parameters including enzyme expression levels, pathway flux distribution, cofactor availability, and cultivation conditions to maximize chlorogenic acid production. By adjusting these parameters in the biological system, the patent achieves high yields that are not attainable through traditional chemical synthesis methods.
3Productivity
If biosynthesis pathways are reconstructed in E. coli, then chlorogenic acid can be produced through metabolic engineering, but the flux of caffeic acid and chlorogenic acid synthesis is unbalanced and many cofactors are consumed
Solution Approach 1:
The patent optimizes pathway flux parameters by balancing the expression levels of key enzymes including HQT, 4CL, and associated pathway enzymes. This parameter optimization ensures balanced flux distribution between caffeic acid and chlorogenic acid synthesis, preventing metabolic bottlenecks and reducing unnecessary cofactor consumption while maintaining high productivity.
Solution Approach 2:
The patent implements metabolic feedback control through balanced pathway design, where the flux through each enzymatic step is regulated to maintain optimal intermediate concentrations. This feedback mechanism prevents accumulation of intermediates and ensures efficient cofactor utilization throughout the biosynthetic pathway.
4Reliability
If endogenous thioesterase is present in E. coli, then the bacterium can perform normal metabolic functions, but caffeoyl-CoA is degraded which limits chlorogenic acid production
Solution Approach 1:
The patent removes the detrimental endogenous thioesterase activity from the E. coli system through genetic knockout or inhibition. By eliminating this enzyme that degrades caffeoyl-CoA, the patent protects the essential precursor for chlorogenic acid synthesis while maintaining the bacterium's overall metabolic functionality through compensatory pathways.
Solution Approach 2:
The patent converts the harmful effect of endogenous thioesterase-mediated caffeoyl-CoA degradation into a benefit by eliminating or suppressing this activity. The removal of this degradation pathway redirects metabolic flux toward chlorogenic acid production, transforming a metabolic liability into a production advantage while the cell maintains essential functions through alternative enzymatic routes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant E. coli strain achieves a chlorogenic acid titer of up to 638.2 mg/L in shake flasks and 2.8 g/L in a 5-L fermenter, providing a robust biosynthesis approach for large-scale production.
Implementation Method 1
hydroxycinnamoyl CoA:quinic acid transferase to condense one molecule of caffeoyl-CoA and one molecule of quinic acid
Implementation Method 2
4-coumarate:CoA ligase At4CL1 derived from Arabidopsis thaliana
Implementation Method 3
the application of recombinant E. coli for producing chlorogenic acid or derivatives thereof by fermentation
Data Source
AI summary
The present disclosure provides a recombinant Escherichia coli for producing chlorogenic acid and application thereof. In the present disclosure, tyrosine ammonia-lyase FjTAL derived from Flavobacterium johnsoniae, hpaBC derived from E. coli, 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase mutant aroGfbr, chorismate mutase tyrC derived from Zymomonas mobilis, quinic acid/shikimate-5 dehydrogenase ydiB derived from E. coli, hydroxycinnamoyl CoA:quinic acid transferase NtHQT derived from Nicotiana tabacum, and 4-coumarate:CoA ligase At4CL1 derived from Arabidopsis thaliana are expressed in the recombinant E. coli, thereby constructing a chlorogenic acid biosynthesis pathway in E. coli. Then, the aroB gene and gldA gene derived from E. coli are overexpressed, and an endogenous gene menI is knocked out from the recombinant E. coli. The recombinant strain produced chlorogenic acid by fermentation at a titer of up to 638.2 mg/L in a shake flask or at a titer of 2.8 g/L in a 5-L fermenter.